Clinical Trials Logo
  1. Home
  2. Influenza Infection
  3. NCT04933968

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Influenza Infection Clinical Trial

Official title:
Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Clinical Trial Summary

A study to evaluate ALVR106; an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets four community acquired respiratory viruses: respiratory syncytial virus (RSV), influenza, human metapneumovirus (hMPV), and/or parainfluenza virus (PIV) following hematopoietic cell transplant (HCT) and solid organ transplant (SOT).

Clinical Trial Description

The study hypothesis is that the administration of ALVR106, multi-virus specific T cells, plus standard of care, to post HCT or SOT patients suffering from infection with any of the four targeted viruses (RSV, influenza, hMPV, and/or PIV) will be safe and demonstrate shorter time to resolution of the respiratory viral infection (as measured by resolution of symptoms and viral load clearance in nasal swab) compared to patients treated with placebo. This trial will consist of two parts: Part A is Dose Escalation and Part B is Cohort Expansion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04933968
Study type Interventional
Source AlloVir
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date March 21, 2022
Completion date January 31, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT00603811 - Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults Phase 1
Completed NCT03784885 - A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult Phase 2
Recruiting NCT05436444 - Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model Phase 1
Completed NCT01201902 - A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine Phase 3
Completed NCT00559975 - Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine Phase 1
Terminated NCT00647465 - Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer Phase 3
Recruiting NCT01225770 - Gargling With Green Tea for Prophylaxis of Influenza Infection in Teenagers Phase 3
Completed NCT01008020 - Effects of Tea Catechin Consumption on the Prophylaxis of Influenza Infection N/A
Completed NCT00239213 - Catechin Gargling for Influenza Infection N/A
Not yet recruiting NCT04298060 - DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) Phase 2
Completed NCT01049490 - Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device N/A
Completed NCT02367885 - Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants Phase 1/Phase 2
Completed NCT02313155 - Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults Phase 1/Phase 2
Completed NCT00812448 - Catechin Containing Mask for the Prevention of Influenza Infection N/A
Active, not recruiting NCT05818124 - Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) Phase 1
Terminated NCT01160237 - Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM Phase 3
Completed NCT03814720 - Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults Phase 1